Inactief instrument

Andere talen Tonix Pharmaceuticals Holding Corp Nasdaq

Aandelen

US8902604094

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	15/05
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights	13/05
Tonix Pharmaceuticals : Factsheet	30/04
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase	24/04
Tonix Pharmaceuticals : Investor Presentation April 2024	19/04
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	09/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	01/04
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	28/03
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	28/03
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia	20/03
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024	19/03
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	13/03
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring	12/03
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	11/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tonix Pharmaceuticals Holding Corp Nasdaq

Aandelen

US8902604094

Andere talen

Filters